Company News 01 Dec 2024 Media Release | FDA Approves Implicit Drug for Clinical Study in Heart Failure and First Patient Reported to be Responding Well to Treatment FDA Approves Implicit Drug for Clinical Study in Heart Failure and First Patient Reported to be Responding Well to Treatment Implicit Bioscience
Company News 30 Nov 2023 Media Release: Implicit Uncovers Huge Heart Failure Risk MEDIA RELEASE, 30 November 2023, Brisbane Australia: A study conducted by Implicit Bioscience of more than 90 million patient records… Implicit Bioscience
Company News 24 Nov 2023 New Precision Nuclear Medicine Tool to be Used with Implicit’s Heart Drug Summary: New imaging technology allows clinicians to see immune cells that cause many heart diseases. Implicit’s antibody reprograms these immune… Implicit Bioscience
Company News 24 Nov 2023 Promising New Cardiology Program in Heart-stopping Disease Summary: Arrhythmogenic cardiomyopathy (ACM) causes sudden cardiac death in young adults and has no current drug treatment. Extensive study of… Implicit Bioscience
Company News 13 Jun 2022 Heart Attack Data Presented In Berlin Implicit Bioscience will be in the spotlight this week at the world congress of the International Society for Heart Research… Implicit Bioscience
Company News 08 Nov 2021 IC14 featured in Medicine Journal The US scientific journal Medicine has published a report of the first safety and biomarker study of IC14 in patients with ALS-MND.… Implicit Bioscience
Company News Implicit Bioscience 26 May 2021 Taming the Immune System in COVID-19 and other Serious Diseases The following feature story was written by an experienced biotechnology market commentator in the US, following an interview with Implicit… Implicit Bioscience
Company News 16 Apr 2021 Media Release: IC14 COVID-19 US Clinical Trial Implicit Bioscience is pleased to announce the commencement of its IC14 COVID-19 clinical trials in the US. Implicit Bioscience
Company News 12 Jan 2021 FDA Awards IC14 as Orphan Drug for MND The FDA has designated Brisbane biotech Implicit Bioscience’s biologic IC14 an Orphan Drug for the treatment of motor neurone disease. Implicit Bioscience
Company News 20 Dec 2020 US Defense Department Funds Program for IC14 in Neurotrauma The US Department of Defense has funded a USD 735,000 grant entitled “Danger Signalling, Traumatic Brain Injury (TBI), and Epileptogenesis”. Implicit Bioscience
